Indications › Prediabetes › semaglutide
semaglutide in prediabetes
semaglutide is not approved in the US for prediabetes, and has 10 trials on file here in this condition. 8 of them are phase 3 or later. The next scheduled result is 2026-10-31. Being studied in a condition is not the same as being approved for it; most such programmes end without an approval.
10 registered trials study semaglutide (Rybelsus, Wegovy, Ozempic) in prediabetes, 6 of them still active and 2 in phase 3. The next is due to report 2026-10-31.
- Trials on file
- 10
- Active
- 6
- Active phase 3
- 2
- Participants in active trials
- 1,520
- Sponsors
- 10
- Scheduled readouts
- 1
Scheduled to report
Dates are filed by the sponsor and move often. Each links to its own record and change history.
| Est. completion | Trial | Phase | Participants |
|---|---|---|---|
| 2026-10-31 | Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes NCT05119179 · The University of Texas Health Science Center, Houston | P4 | 300 |
All trials on file
Every registered trial of semaglutide grouped under prediabetes, largest first. Grouping follows the registry’s own condition wording.
See the full record for semaglutide, or every molecule being studied in prediabetes. These are registered trials, nothing more. Most drugs tested in a new condition never get approved for it, and plenty of these will report nothing useful.